Association of metabolic syndrome with sensory gating deficits in patients with chronic schizophrenia

Psychoneuroendocrinology

Volumn 57, Issue , 2015, Pages 125-133

  Micoulaud Franchi, Jean Arthur ^a,b,c   Faugere, Mélanie ^d,e   Boyer, Laurent ^e   Cermolacce, Michel ^a,d,f   Richieri, Raphaëlle ^d,e   Faget, Catherine ^d,e   Philip, Pierre ^b,c   Vion Dury, Jean ^a,d,f   Lancon, Christophe ^d,e  

^a HÔPITAL SAINTE MARGUERITE   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^e AIX MARSEILLE UNIVERSITY   (France)

^f CNRS   (France)

Author keywords

Cognitive functioning; Metabolic syndrome; P50 suppression; Schizophrenia; Sensory gating

Indexed keywords

CLOZAPINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; TRIACYLGLYCEROL;

ABDOMINAL OBESITY; ADULT; AGE DISTRIBUTION; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTEROL BLOOD LEVEL; COGNITIVE DEFECT; CONTROLLED STUDY; DISEASE ASSOCIATION; EVOKED AUDITORY RESPONSE; EXECUTIVE FUNCTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY CONSOLIDATION; METABOLIC SYNDROME X; PREVALENCE; PRIORITY JOURNAL; SCHIZOPHRENIA; SENSORY GATING DEFICIT; TASK PERFORMANCE; TRIACYLGLYCEROL BLOOD LEVEL; AGED; CHRONIC DISEASE; COGNITION; EVOKED RESPONSE; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; SENSORY GATING; YOUNG ADULT;

ADULT; AGED; CHRONIC DISEASE; COGNITION; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SCHIZOPHRENIA; SENSORY GATING; YOUNG ADULT;

EID: 84929333314     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.04.005     Document Type: Article

References (57)

1. Adcock R.A., Dale C., Fisher M., Aldebot S., Genevsky A., Simpson G.V., Nagarajan S., Vinogradov S. When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia. Schizophr. Bull. 2009, 35(6):1132-1141.
2. Adler L.E., Hoffer L.D., Wiser A., Freedman R. Normalization of auditory physiology by cigarette smoking in schizophrenic patients. Am. J. Psychiatry 1993, 150(12):1856-1861.
3. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorder 2000, American Psychiatric Association, Washington, DC., (Text Revision (DSM-IV-TR)). fourth ed.
4. Balkau B., Vernay M., Mhamdi L., Novak M., Arondel D., Vol S., Tichet J., Eschwege E. The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study. Diabetes Metab. 2003, 29(5):526-532.
5. Boyer L., Richieri R., Dassa D., Boucekine M., Fernandez J., Vaillant F., Padovani R., Auquier P., Lancon C. Association of metabolic syndrome and inflammation with neurocognition in patients with schizophrenia. Psychiatry Res. 2013, 210(2):381-386.
6. Boyer L., Testart J., Michel P., Richieri R., Faget-Agius C., Vanoye V., Auquier P., Lancon C., Guedj E. Neurophysiological correlates of metabolic syndrome and cognitive impairment in schizophrenia: a structural equation modeling approach. Psychoneuroendocrinology 2014, 50:95-105.
7. Clementz B.A., Geyer M.A., Braff D.L. P50 suppression among schizophrenia and normal comparison subjects: a methodological analysis. Biol. Psychiatry 1997, 41(10):1035-1044.
8. Cotter J., Drake R.J., Bucci S., Firth J., Edge D., Yung A.R. What drives poor functioning in the at-risk mental state? A systematic review. Schizophr. Res. 2014, 159(2-3):267-277.
9. Cullum C.M., Harris J.G., Waldo M.C., Smernoff E., Madison A., Nagamoto H.T., Griffith J., Adler L.E., Freedman R. Neurophysiological and neuropsychological evidence for attentional dysfunction in schizophrenia. Schizophr. Res. 1993, 10(2):131-141.
10. Davis J.M. Comparative doses and costs of antipsychotic medication. Arch. Gen. Psychiatry 1976, 33(7):858-861.
11. Dickinson D., Iannone V.N., Wilk C.M., Gold J.M. General and specific cognitive deficits in schizophrenia. Biol. Psychiatry 2004, 55(8):826-833.
12. Dipasquale S., Pariante C.M., Dazzan P., Aguglia E., McGuire P., Mondelli V. The dietary pattern of patients with schizophrenia: a systematic review. J. Psychiatr. Res. 2013, 47(2):197-207.
13. Erwin R.J., Turetsky B.I., Moberg P., Gur R.C., Gur R.E. P50 abnormalities in schizophrenia: relationship to clinical and neuropsychological indices of attention. Schizophr. Res. 1998, 33(3):157-167.
14. Fisher M., Holland C., Merzenich M.M., Vinogradov S. Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia. Am. J. Psychiatry 2009, 166(7):805-811.
15. Freedman R., Adler L.E., Gerhardt G.A., Waldo M., Baker N., Rose G.M., Drebing C., Nagamoto H., Bickford-Wimer P., Franks R. Neurobiological studies of sensory gating in schizophrenia. Schizophr. Bull. 1987, 13(4):669-678.
16. Freedman R., Adler L.E., Waldo M.C., Pachtman E., Franks R.D. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol. Psychiatry 1983, 18(5):537-551.
17. Friedman J.I., Wallenstein S., Moshier E., Parrella M., White L., Bowler S., Gottlieb S., Harvey P.D., McGinn T.G., Flanagan L., Davis K.L. The effects of hypertension and body mass index on cognition in schizophrenia. Am. J. Psychiatry 2012, 167(10):1232-1239.
18. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80(1):45-53.
19. Grundy S.M., Cleeman J.I., Daniels S.R., Donato K.A., Eckel R.H., Franklin B.A., Gordon D.J., Krauss R.M., Savage P.J., Smith S.C., Spertus J.A., Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112(17):2735-2752.
20. Heatherton T.F., Kozlowski L.T., Frecker R.C., Fagerstrom K.O. The Fagerstrom test for nicotine dependence: a revision of the Fagerstrom tolerance questionnaire. Br. J. Addict. 1991, 86(9):1119-1127.
21. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12(3):426-445.
22. Hetrick W.P., Erickson M.A., Smith D.A. Phenomenological dimensions of sensory gating. Schizophr. Bull. 2012, 38(1):178-191.
23. Javitt D., Freedman R. Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia. Am. J. Psychiatry 2014, 10.1176/appi.ajp.2014.13121691.
24. Katz M. Multivariable Analysis: A Practical Guide for Clinicians and Public Health Researchers 2011, Cambridge University Press, Cambridge.
25. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
26. Labouesse M.A., Stadlbauer U., Langhans W., Meyer U. Chronic high fat diet consumption impairs sensorimotor gating in mice. Psychoneuroendocrinology 2013, 38(11):2562-2574.
27. Lancon C., Aghababian V., Llorca P.M., Auquier P. Factorial structure of the positive and negative syndrome scale (PANSS): a forced five-dimensional factor analysis. Acta Psychiatr. Scand. 1998, 98(5):369-376.
28. Lancon C., Dassa D., Fernandez J., Richieri R., Padovani R., Boyer L. Are cardiovascular risk factors associated with verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovasc. Psychiatry Neurol. 2012, 204043. 10.1155/2012/204043.
29. Li C., Zhan G., Rao S., Zhang H. Metabolic syndrome and its factors affect cognitive function in chronic schizophrenia complicated by metabolic syndrome. J. Nerv. Ment. Dis. 2014, 202(4):313-318.
30. Light G.A., Braff D. Sensory gating deficits in schizophrenia: can we parse the effects of medication, nicotine use, and changes in clinical status. Clin. Neurosci. Res. 2003, 3(1):47-54.
31. Lindenmayer J.P., Khan A., Kaushik S., Thanju A., Praveen R., Hoffman L., Cherath L., Valdez G., Wance D. Relationship between metabolic syndrome and cognition in patients with schizophrenia. Schizophr. Res. 2012, 142(1-3):171-176.
32. Lopresti A.L., Drummond P.D. Obesity and psychiatric disorders: commonalities in dysregulated biological pathways and their implications for treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2013, 45:92-99.
33. McEvoy J.P., Meyer J.M., Goff D.C., Nasrallah H.A., Davis S.M., Sullivan L., Meltzer H.Y., Hsiao J., Scott Stroup T., Lieberman J.A. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr. Res. 2005, 80(1):19-32.
34. Medeiros-Ferreira L., Obiols J.E., Navarro-Pastor J.B., Zuniga-Lagares A. Metabolic syndrome and health-related quality of life in patients with schizophrenia. Actas Esp. Psiquiatr. 2013, 41(1):17-26.
35. Micoulaud Franchi J.A., Aramaki M., Geoffroy P., Richieri R., Cermolacce M., Faget-Agius C., Ystad S., Kronland-Martinet R., Lançon C., Vion Dury J. Effects of clozapine on perceptual abnormalities and sensory gating. A preliminary cross-sectional study in schizophrenia. J. Clin. Psychopharmacol. 2015, 35(2):184-187.
36. Micoulaud-Franchi J.A., Hetrick W.P., Aramaki M., Bolbecker A., Boyer L., Ystad S., Kronland-Martinet R., Richieri R., Faget C., Faugere M., El-Kaim A., Cermolacce M., Lancon C., Vion-Dury J. Do schizophrenia patients with low P50-suppression report more perceptual anomalies with the sensory gating inventory?. Schizophr. Res. 2014, 157(1-3):157-162.
37. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2013, 39(2):306-318.
38. Nasrallah H.A. Linkage of cognitive impairments with metabolic disorders in schizophrenia. Am. J. Psychiatry 2010, 167(10):1155-1157.
39. Nelson B., Whitford T.J., Lavoie S., Sass L.A. What are the neurocognitive correlates of basic self-disturbance in schizophrenia? Integrating phenomenology and neurocognition: Part 2 (aberrant salience). Schizophr. Res. 2014, 152(1):20-27.
40. Nuechterlein K.H., Barch D.M., Gold J.M., Goldberg T.E., Green M.F., Heaton R.K. Identification of separable cognitive factors in schizophrenia. Schizophr. Res. 2004, 72(1):29-39.
41. Patterson J.V., Hetrick W.P., Boutros N.N., Jin Y., Sandman C., Stern H., Potkin S., Bunney W.E. P50 sensory gating ratios in schizophrenics and controls: a review and data analysis. Psychiatry Res. 2008, 158(2):226-247.
42. Peduzzi P., Concato J., Kemper E., Holford T.R., Feinstein A.R. A simulation study of the number of events per variable in logistic regression analysis. J. Clin. Epidemiol. 1996, 49(12):1373-1379.
43. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br. J. Psychiatry Suppl. 2004, 47:S102-S105.
44. Peet M. International variations in the outcome of schizophrenia and the prevalence of depression in relation to national dietary practices: an ecological analysis. Br. J. Psychiatry 2004, 184:404-408.
45. Postmes L., Sno H.N., Goedhart S., van der Stel J., Heering H.D., de Haan L. Schizophrenia as a self-disorder due to perceptual incoherence. Schizophr. Res. 2014, 152(1):41-50.
46. Ramos-Rodriguez J.J., Ortiz O., Jimenez-Palomares M., Kay K.R., Berrocoso E., Murillo-Carretero M.I., Perdomo G., Spires-Jones T., Cozar-Castellano I., Lechuga-Sancho A.M., Garcia-Alloza M. Differential central pathology and cognitive impairment in pre-diabetic and diabetic mice. Psychoneuroendocrinology 2013, 38(11):2462-2475.
47. Sanchez-Morla E.M., Santos J.L., Aparicio A., Garcia-Jimenez M.A., Soria C., Arango C. Neuropsychological correlates of P50 sensory gating in patients with schizophrenia. Schizophr. Res. 2013, 143(1):102-106.
48. Sharma A.N., Elased K.M., Garrett T.L., Lucot J.B. Neurobehavioral deficits in db/db diabetic mice. Physiol. Behav. 2010, 101(3):381-388.
49. Smith A.K., Edgar J.C., Huang M., Lu B.Y., Thoma R.J., Hanlon F.M., McHaffie G., Jones A.P., Paz R.D., Miller G.A., Canive J.M. Cognitive abilities and 50- and 100-msec paired-click processes in schizophrenia. Am. J. Psychiatry 2010, 167(10):1264-1275.
50. Szoke A., Trandafir A., Dupont M.E., Meary A., Schurhoff F., Leboyer M. Longitudinal studies of cognition in schizophrenia: meta-analysis. Br. J. Psychiatry 2008, 192(4):248-257.
51. Tan S.P., Jie-Feng C., Fan F.M., Zhao Y.L., Chen N., Fan H.Z., Zhang J.G., Wang Y.H., Yoon J.H., Soares J.C., Zou Y.Z., Zhang X.Y. Smoking, MATRICS consensus cognitive battery and P50 sensory gating in a Han Chinese population. Drug Alcohol Depend. 2014, 143:51-57.
52. Thakore J.H. Metabolic syndrome and schizophrenia. Br. J. Psychiatry 2005, 186:455-456.
53. Witte A.V., Fobker M., Gellner R., Knecht S., Floel A. Caloric restriction improves memory in elderly humans. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(4):1255-1260.
54. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667.
55. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., Tylavsky F.A., Newman A.B. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 2004, 292(18):2237-2242.
56. Young S.L., Taylor M., Lawrie S.M. First do no harm. A systematic review of the prevalence and management of antipsychotic adverse effects. J. Psychopharmacol. 2015, 29(4):353-362.
57. Yung A.R., Fusar-Poli P., Nelson B. The ultra high risk approach to define psychosis risk. Curr. Pharm. Des. 2012, 18(4):346-350.